{'fraction_non_alphanumeric': 0.022357723577235773, 'fraction_numerical': 0.01016260162601626, 'mean_word_length': 4.659003831417625, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Interferon versus interferon and UDCA combined therapy in chronic hepatitis C.

BACKGROUND
Interferon alpha (IFN) has been shown to have established efficacy in the treatment of chronic hepatitis C but its effectiveness is unsatisfactory. Combined therapies with IFN and other antiviral or immunomodulatory drugs are under evaluation. A combination of interferon alpha and ursodeoxycholic acid UDCA has been reported to give better results than interferon alone. The aim of the study was to assess the efficacy of IFN monotherapy versus IFN and UDCA therapy in patients with chronic hepatitis C.


MATERIAL AND METHODS
We studied 38 patients (25 males and 13 females) chronically infected with HCV (anti-HCV positive, HCV-RNA positive by PCR). Seventeen of them were treated with IFN 3 MU tiw for 6 months--Group I. The remaining 21 patients were treated with IFN, at the same dosage, plus UDCA (10 mg/kg/day) also for 6 months--Group II. Patients were followed for 6 months. 6 months after the end of therapy, laboratory biochemical parameters, HCV viremia and proportion as well as time to relapse were assessed.


CONCLUSIONS
In contrast to previous reports we did not find any differences neither in proportion of HCV reactivation nor in the time of its appearance among patients treated because of chronic hepatitis B with IFN alone or with IFN plus UDCA combined therapy. We also did not find any difference in initial and late response to the treatments in both groups.